Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamidreza Ghalyanchi Langroodi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Translational Medicine|September 13, 2024
Repeated prefrontal tDCS for improving mental health and cognitive deficits in multiple sclerosis: a randomized, double-blind, parallel-group studyNasim Zakibakhsh, Sajjad Basharpoor, Hamidreza Ghalyanchi Langroodi, et al.
Basic and Clinical Neuroscience|July 29, 2024
Brain MRI Volumetric Assessment of Patients With Multiple Sclerosis: The Volume of Basal Ganglia, Thalamus, and Posterior FossaSima Fallah Arzpeyma, Sara Janeshin, Niusheh Soofi Afshar, et al.
Acta Neurologica Belgica|June 17, 2016
Neuromyelitis optica and pregnancyAmeneh Zare-Shahabadi, Hamidreza Ghalyanchi Langroodi, Amir Reza Azimi, et al.
Multiple Sclerosis and Related Disorders|September 1, 2024
Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY)Vahid Shaygannejad, Fereshteh Ashtari, Morteza Saeidi, et al.
Multiple Sclerosis and Related Disorders|December 13, 2021
Characteristics of COVID-19 in patients with multiple sclerosisFereshteh Ghadiri, Mohammad Ali Sahraian, Vahid Shaygannejad, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendationsMohammad Ali Sahraian, Abdorreza Naser Moghadasi, Amir Reza Azimi, et al.
Scientific Reports|October 22, 2024
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trialMohammad Ali Sahraian, Roya Abolfazli, Vahid Shaygannejad, et al.
Current Journal of Neurology|November 27, 2023
Iranian specialists' approach to treatment escalation in multiple sclerosis patients with cognitive impairmentFereshteh Ghadiri, Elnaz Asadollahzadeh, Zahra Ebadi, et al.
Current Journal of Neurology|November 27, 2023
Iranian specialists' approach to surgery in patients with multiple sclerosisFereshteh Ghadiri, Zahra Ebadi, Elnaz Asadollahzadeh, et al.
Multiple Sclerosis and Related Disorders|November 20, 2025
Infection screening prior to Ocrelizumb initiation in patients with Multiple Sclerosis (MS): Concise clinical recommendation based on a modified Delphi consensus on behalf of the Iranian MS -infectious disease groupSepideh Paybast, Marzie Abutorabi-Zarchi, Fereshteh Ashtari, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Translational Medicine|September 13, 2024
Repeated prefrontal tDCS for improving mental health and cognitive deficits in multiple sclerosis: a randomized, double-blind, parallel-group studyNasim Zakibakhsh, Sajjad Basharpoor, Hamidreza Ghalyanchi Langroodi, et al.
Basic and Clinical Neuroscience|July 29, 2024
Brain MRI Volumetric Assessment of Patients With Multiple Sclerosis: The Volume of Basal Ganglia, Thalamus, and Posterior FossaSima Fallah Arzpeyma, Sara Janeshin, Niusheh Soofi Afshar, et al.
Acta Neurologica Belgica|June 17, 2016
Neuromyelitis optica and pregnancyAmeneh Zare-Shahabadi, Hamidreza Ghalyanchi Langroodi, Amir Reza Azimi, et al.
Multiple Sclerosis and Related Disorders|September 1, 2024
Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY)Vahid Shaygannejad, Fereshteh Ashtari, Morteza Saeidi, et al.
Multiple Sclerosis and Related Disorders|December 13, 2021
Characteristics of COVID-19 in patients with multiple sclerosisFereshteh Ghadiri, Mohammad Ali Sahraian, Vahid Shaygannejad, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendationsMohammad Ali Sahraian, Abdorreza Naser Moghadasi, Amir Reza Azimi, et al.
Scientific Reports|October 22, 2024
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trialMohammad Ali Sahraian, Roya Abolfazli, Vahid Shaygannejad, et al.
Current Journal of Neurology|November 27, 2023
Iranian specialists' approach to treatment escalation in multiple sclerosis patients with cognitive impairmentFereshteh Ghadiri, Elnaz Asadollahzadeh, Zahra Ebadi, et al.
Current Journal of Neurology|November 27, 2023
Iranian specialists' approach to surgery in patients with multiple sclerosisFereshteh Ghadiri, Zahra Ebadi, Elnaz Asadollahzadeh, et al.
Multiple Sclerosis and Related Disorders|November 20, 2025
Infection screening prior to Ocrelizumb initiation in patients with Multiple Sclerosis (MS): Concise clinical recommendation based on a modified Delphi consensus on behalf of the Iranian MS -infectious disease groupSepideh Paybast, Marzie Abutorabi-Zarchi, Fereshteh Ashtari, et al.
Pageof 2